Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4074)
All Articles published online
|
Jun 21, 2008 (publication date) through Dec 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008; 14(23): 3681-3692 [PMID: 18595135 DOI: 10.3748/wjg.14.3681] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i23/3681.htm |
| Number | Citing Articles |
| 1 |
Maria Graziella Catalano, Mariateresa Pugliese, Eleonora Gargantini, Cristina Grange, Benedetta Bussolati, Sofia Asioli, Ornella Bosco, Roberta Poli, Alessandra Compagnone, Andrea Bandino, Franco Mainini, Nicoletta Fortunati, Giuseppe Boccuzzi. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. International Journal of Cancer 2012; 130(3): 694 doi: 10.1002/ijc.26057
|
| 2 |
Yudibeth Sixto-López, Martiniano Bello, José Correa-Basurto. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking. Journal of Biomolecular Structure and Dynamics 2019; 37(3): 584 doi: 10.1080/07391102.2018.1441072
|
| 3 |
Dmitriy I Dovzhanskiy, Stefanie M Arnold, Thilo Hackert, Ina Oehme, Olaf Witt, Klaus Felix, Nathalia Giese, Jens Werner. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-226
|
| 4 |
Lubna Wasim, Madhu Chopra. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. Biomedicine & Pharmacotherapy 2016; 84: 1393 doi: 10.1016/j.biopha.2016.10.057
|
| 5 |
Elisabeth Hessmann, Steven A Johnsen, Jens T Siveke, Volker Ellenrieder. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?. Gut 2017; 66(1): 168 doi: 10.1136/gutjnl-2016-312539
|
| 6 |
Günter Schneider, Oliver H. Krämer, Petra Fritsche, Susanne Schüler, Roland M. Schmid, Dieter Saur. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine 2010; 14(6a): 1255 doi: 10.1111/j.1582-4934.2009.00974.x
|
| 7 |
Ouaïssi Mehdi, Silvy Françoise, Costa Lima Sofia, Giger Urs, Zemmour Kevin, Sastre Bernard, Sielezneff Igor, Cordeiro-da-Silva Anabela, Lombardo Dominique, Mas Eric, Ouaïssi Ali. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology 2012; 12(2): 146 doi: 10.1016/j.pan.2012.02.013
|
| 8 |
Weiqiang Zhou, I-Chau Liang, Nelson S. Yee. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biology & Therapy 2011; 11(7): 659 doi: 10.4161/cbt.11.7.14720
|
| 9 |
Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L Petrillo, Delong Liu. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology & Oncology 2010; 3(1) doi: 10.1186/1756-8722-3-5
|
| 10 |
Ahmed Abdullah Ahmed, Stephen Neidle. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells. Molecules 2020; 25(22): 5407 doi: 10.3390/molecules25225407
|
| 11 |
Georg Feldmann, Anirban Maitra. Drug Discovery in Pancreatic Cancer. 2010; : 181 doi: 10.1007/978-1-4419-1160-5_10
|
| 12 |
Avineesh Singh, Vijay K. Patel, Deepak K. Jain, Preeti Patel, Harish Rajak. Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects. Oncology and Therapy 2016; 4(1): 73 doi: 10.1007/s40487-016-0023-1
|
| 13 |
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami, Dimitrios Dimitroulis. Pharmacoepigenetics. 2019; : 501 doi: 10.1016/B978-0-12-813939-4.00013-9
|
| 14 |
M. Cecilia Crisanti, Africa F. Wallace, Veena Kapoor, Fabian Vandermeers, Melissa L. Dowling, Luana P. Pereira, Kara Coleman, Barbara G. Campling, Zvi G. Fridlender, Gary D. Kao, Steven M. Albelda. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cellsin vitroandin vivowith particular efficacy for small cell lung cancer. Molecular Cancer Therapeutics 2009; 8(8): 2221 doi: 10.1158/1535-7163.MCT-09-0138
|
| 15 |
Yi Zou, Gillian M. Howell, Lisa E. Humphrey, Jing Wang, Michael G. Brattain, Lu-Zhe Sun. Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi). PLoS ONE 2013; 8(7): e69992 doi: 10.1371/journal.pone.0069992
|
| 16 |
Qi Xie, Lin Jia, Yan-Hong Liu, Cheng-Gang Wei. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer <italic>in vivo</italic>. World Journal of Gastroenterology 2009; 15(6): 737-741 doi: 10.3748/wjg.15.737
|
| 17 |
Paola Neri, Nizar J Bahlis, Sagar Lonial. Panobinostat for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 2012; 21(5): 733 doi: 10.1517/13543784.2012.668883
|
| 18 |
Shabir Ahmad Ganai. Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy. 2020; : 173 doi: 10.1007/978-981-15-8179-3_9
|
| 19 |
Jasmijn G.M. van Kampen, Monica A.J. Marijnissen-van Zanten, Femke Simmer, Winette T.A. van der Graaf, Marjolijn J.L. Ligtenberg, Iris D. Nagtegaal. Epigenetic targeting in pancreatic cancer. Cancer Treatment Reviews 2014; 40(5): 656 doi: 10.1016/j.ctrv.2013.12.002
|
| 20 |
Antonino Grassadonia, Pasquale Cioffi, Felice Simiele, Laura Iezzi, Marinella Zilli, Clara Natoli. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers 2013; 5(3): 919 doi: 10.3390/cancers5030919
|
| 21 |
Dennis R. Grayson, Marija Kundakovic, Rajiv P. Sharma. Is There a Future for Histone Deacetylase Inhibitors in the Pharmacotherapy of Psychiatric Disorders?. Molecular Pharmacology 2010; 77(2): 126 doi: 10.1124/mol.109.061333
|
| 22 |
Joana N.R. Dias, Sandra I. Aguiar, Diane M. Pereira, Ana S. André, Lurdes Gano, João D.G. Correia, Belmira Carrapiço, Barbara Rütgen, Rui Malhó, Conceição Peleteiro, João Goncalves, Cecília M.P. Rodrigues, Solange Gil, Luís Tavares, Frederico Aires-da-Silva. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 2018; 9(47): 28586 doi: 10.18632/oncotarget.25580
|